Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS)

Please see the May 2012 FDA safety communication concerning Gilenya

Gilenya (jill-LEN-nee-ya, fingolimod) is the first ORAL drug to reduce relapses in relapsing multiple sclerosis (MS).

It's a new immune modulator that prevents some white blood cells from migrating to the CNS and damaging it.

Gilenya is approved for first-line use...but don't expect it to replace beta-interferons (Avonex, etc) or Copaxone (glatiramer). These drugs have a longer safety record and they're less expensive.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote